KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
19.24
+0.08 (0.42%)
At close: Apr 28, 2026, 4:00 PM EDT
19.56
+0.32 (1.66%)
After-hours: Apr 28, 2026, 5:39 PM EDT
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 275 employees as of December 31, 2025. The number of employees increased by 5 or 1.85% since the number was reported on April 30, 2025.
Employees
275
Change
5
Growth
1.85%
Revenue / Employee
$267,698
Profits / Employee
-$597,404
Market Cap
985.52M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Xeris Biopharma Holdings | 435 |
| Phathom Pharmaceuticals | 371 |
| Xencor | 260 |
| Geron | 258 |
| Omeros | 175 |
| Zenas BioPharma | 167 |
| ORIC Pharmaceuticals | 104 |
KALV News
- 13 days ago - KalVista Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 20 days ago - KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - Business Wire
- 26 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Transcript: Transition period - Transcripts
- 4 weeks ago - KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - Business Wire